The cost of vaccinating a child in the world's poorest countries is much higher than it was in 2001--68 times higher, according to Medecins Sans Frontieres. The international charity has a problem with that, and it's asking pneumococcal disease vaccine makers Pfizer and GlaxoSmithKline to fix it.
The early success of a Unicef program to bring pneumococcal vaccines to poor countries has created a problem for the agency--demand is outstripping supply. To fix the problem, Unicef has negotiated new deals with GlaxoSmithKline and Pfizer, securing more vaccines at lower costs.
Results from the first randomized controlled European clinical trial of GlaxoSmithKline's ($GSK) pneumococcal conjugate vaccine show it's highly effective when it comes to preventing invasive pneumococcal disease in infants younger than age 2.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales.
As H1 came to a close, FierceVaccines decided to take a look at which prophylactic vaccines flew off the shelves--and which companies made the sales. Take a look at the full list >>
Argentina's government has fined GlaxoSmithKline ($GSK) $93,000 for its management of trials of the vaccine Synflorix in which 14 babies died. This case brings to light questions as to how big...
Just in time for the holiday season, Pfizer ($PFE) and GlaxoSmithKline ($GSK) said they are selling an additional 360 million doses of their pneumonia vaccine to a global health organization at a
When a vaccine that guards against the most common causes of pneumococcal disease comes to the market, it's simultaneously creating fresh opportunities for strains not covered in the shot, scientists
GlaxoSmithKline made a splash in the media several months ago when it joined with Pfizer and announced that it would supply 30 million doses of vaccine each year to protect children in developing
Over the next 10 years, kids in developing countries will see a stream of discounted vaccines from Pfizer and GlaxoSmithKline. The two drugmakers have inked a long-term vaccine deal with the GAVI